ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0379

Physical Activity Is Associated with Physical and Global Function in Patients with Axial Spondyloarthritis, Independent of Disease Activity
Abstract Number: 0380

Changes in Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Ixekizumab in a Real-World US Cohort
Abstract Number: 0381

Most Disease Outcome Measures but Not ASDAS Are Influenced by Gender in Patients with Axial SpA: Results from ASAS-PerSpA
Abstract Number: 0382

Factors Associated with Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability
Abstract Number: 0383

Analysis of the Performance of an Artificial Intelligence Algorithm for the Detection of Radiographic Sacroiliitis in an Independent Cohort of axSpA Patients Including Both Nr-axSpA and r-axSpA
Abstract Number: 0384

Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study
Abstract Number: 0385

T Cell Receptor Sequencing Identifies Two Classes of T Cells Enriched in HLA-B27-associated Inflammation
Abstract Number: 0386

Quantitative Proteomic Screening Uncovers Diagnostic and Monitoring Serum Biomarkers of Ankylosing Spondylitis
Abstract Number: 0387

Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity
Abstract Number: 0388

Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States
Abstract Number: 0389

Vaccine Effectiveness Among Patients with Psoriatic Disease: A Population-based Study
Abstract Number: 0390

Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients
Abstract Number: 0391

Dynamics of Nail Psoriasis with Guselkumab Treatment and Withdrawal in Association with Skin Response and Patient-reported Outcomes Based on a post Hoc Analysis of Clinical Trial Data
Abstract Number: 0392

Performance of Clinical, Laboratory and Imaging Features for the Diagnosis of Axial Spondyloarthritis – A Systematic Literature Review
Abstract Number: 0393

Are We Meeting Patients’ Treatment Goals with Guideline-Based Therapy for Psoriatic Arthritis?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].